vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Perella Weinberg Partners is the larger business by last-quarter revenue ($219.2M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.9%). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
ESPR vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $219.2M |
| Net Profit | — | $13.8M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 8.5% |
| Net Margin | — | 6.3% |
| Revenue YoY | 143.7% | -2.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $219.2M | ||
| Q3 25 | $87.3M | $164.6M | ||
| Q2 25 | $82.4M | $155.3M | ||
| Q1 25 | $65.0M | $211.8M | ||
| Q4 24 | $69.1M | $225.7M | ||
| Q3 24 | $51.6M | $278.2M | ||
| Q2 24 | $73.8M | $272.0M | ||
| Q1 24 | $137.7M | $102.1M |
| Q4 25 | — | $13.8M | ||
| Q3 25 | $-31.3M | $6.0M | ||
| Q2 25 | $-12.7M | $2.7M | ||
| Q1 25 | $-40.5M | $17.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $16.4M | ||
| Q2 24 | $-61.9M | $-66.0M | ||
| Q1 24 | $61.0M | $-35.8M |
| Q4 25 | 50.6% | 8.5% | ||
| Q3 25 | -11.4% | 5.4% | ||
| Q2 25 | 8.6% | 5.8% | ||
| Q1 25 | -34.0% | 5.5% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 12.9% | ||
| Q2 24 | 3.5% | -30.2% | ||
| Q1 24 | 52.5% | -52.4% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | -35.9% | 3.6% | ||
| Q2 25 | -15.4% | 1.8% | ||
| Q1 25 | -62.2% | 8.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 5.9% | ||
| Q2 24 | -83.9% | -24.3% | ||
| Q1 24 | 44.3% | -35.1% |
| Q4 25 | $0.32 | $0.11 | ||
| Q3 25 | $-0.16 | $0.08 | ||
| Q2 25 | $-0.06 | $0.04 | ||
| Q1 25 | $-0.21 | $0.24 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $0.24 | ||
| Q2 24 | $-0.33 | $-1.21 | ||
| Q1 24 | $0.34 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $255.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-127.4M |
| Total Assets | $465.9M | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $255.9M | ||
| Q3 25 | $92.4M | $185.5M | ||
| Q2 25 | $86.1M | $145.0M | ||
| Q1 25 | $114.6M | $111.2M | ||
| Q4 24 | $144.8M | $407.4M | ||
| Q3 24 | $144.7M | $335.1M | ||
| Q2 24 | $189.3M | $185.3M | ||
| Q1 24 | $226.6M | $156.7M |
| Q4 25 | $-302.0M | $-127.4M | ||
| Q3 25 | $-451.4M | $-302.4M | ||
| Q2 25 | $-433.5M | $-318.4M | ||
| Q1 25 | $-426.2M | $-323.1M | ||
| Q4 24 | $-388.7M | $-421.4M | ||
| Q3 24 | $-370.2M | $-360.8M | ||
| Q2 24 | $-344.2M | $-283.0M | ||
| Q1 24 | $-294.3M | $161.9M |
| Q4 25 | $465.9M | $797.6M | ||
| Q3 25 | $364.0M | $650.2M | ||
| Q2 25 | $347.1M | $606.7M | ||
| Q1 25 | $324.0M | $570.5M | ||
| Q4 24 | $343.8M | $876.8M | ||
| Q3 24 | $314.1M | $810.9M | ||
| Q2 24 | $352.3M | $645.5M | ||
| Q1 24 | $373.1M | $583.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $34.8M |
| Free Cash FlowOCF − Capex | — | $30.5M |
| FCF MarginFCF / Revenue | — | 13.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $34.8M | ||
| Q3 25 | $-4.3M | $59.2M | ||
| Q2 25 | $-31.4M | $56.1M | ||
| Q1 25 | $-22.6M | $-176.5M | ||
| Q4 24 | $-35.0M | $223.4M | ||
| Q3 24 | $-35.3M | $200.3M | ||
| Q2 24 | $-7.2M | $90.0M | ||
| Q1 24 | $53.8M | $-206.3M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $57.6M | ||
| Q2 25 | — | $55.3M | ||
| Q1 25 | — | $-177.6M | ||
| Q4 24 | — | $207.0M | ||
| Q3 24 | $-35.5M | $199.3M | ||
| Q2 24 | $-7.3M | $83.7M | ||
| Q1 24 | $53.8M | $-214.8M |
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 35.0% | ||
| Q2 25 | — | 35.6% | ||
| Q1 25 | — | -83.8% | ||
| Q4 24 | — | 91.7% | ||
| Q3 24 | -68.7% | 71.6% | ||
| Q2 24 | -9.9% | 30.8% | ||
| Q1 24 | 39.0% | -210.3% |
| Q4 25 | 0.0% | 2.0% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 7.3% | ||
| Q3 24 | 0.3% | 0.4% | ||
| Q2 24 | 0.1% | 2.3% | ||
| Q1 24 | 0.1% | 8.3% |
| Q4 25 | — | 2.52× | ||
| Q3 25 | — | 9.85× | ||
| Q2 25 | — | 20.50× | ||
| Q1 25 | — | -10.18× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 12.23× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PWP
Segment breakdown not available.
